title: Nanocarriers for the treatment of glioblastoma multiforme: Current state-of-the-art.
abstract: Glioblastoma multiforme, a grade IV glioma, is the most frequently occurring and invasive primary tumor of the central nervous system, which causes about 4% of cancer-associated-deaths, making it one of the most fatal cancers. With present treatments, using state-of-the-art technologies, the median survival is about 14 months and 2 year survival rate is merely 3-5%. Hence, novel therapeutic approaches are urgently necessary. However, most drug molecules are not able to cross the blood-brain barrier, which is one of the major difficulties in glioblastoma treatment. This review describes the features of blood-brain barrier, and its anatomical changes with different stages of tumor growth. Moreover, various strategies to improve brain drug delivery i.e. tight junction opening, chemical modification of the drug, efflux transporter inhibition, convection-enhanced delivery, craniotomy-based drug delivery and drug delivery nanosystems are discussed. Nanocarriers are one of the highly potential drug transport systems that have gained huge research focus over the last few decades for site specific drug delivery, including drug delivery to the brain. Properly designed nanocolloids are capable to cross the blood-brain barrier and specifically deliver the drug in the brain tumor tissue. They can carry both hydrophilic and hydrophobic drugs, protect them from degradation, release the drug for sustained period, significantly improve the plasma circulation half-life and reduce toxic effects. Among various nanocarriers, liposomes, polymeric nanoparticles and lipid nanocapsules are the most widely studied, and are discussed in this review. For each type of nanocarrier, a general discussion describing their composition, characteristics, types and various uses is followed by their specific application to glioblastoma treatment. Moreover, some of the main challenges regarding toxicity and standardized evaluation techniques are narrated in brief.
authors.affiliation: Laboratory of Pharmaceutical Technology and Biopharmacy, CIRM, University of Liège, 4000, Belgium. Electronic address: reatul.karim@ulg.ac.be.
authors.forename: Reatul
authors.initials: R
authors.lastname: Karim
authors.affiliation: Laboratory of Pharmaceutical Technology and Biopharmacy, CIRM, University of Liège, 4000, Belgium. Electronic address: claudio.palazzo@ulg.ac.be.
authors.forename: Claudio
authors.initials: C
authors.lastname: Palazzo
authors.affiliation: Laboratory of Pharmaceutical Technology and Biopharmacy, CIRM, University of Liège, 4000, Belgium.
authors.forename: Brigitte
authors.initials: B
authors.lastname: Evrard
authors.affiliation: Laboratory of Pharmaceutical Technology and Biopharmacy, CIRM, University of Liège, 4000, Belgium.
authors.forename: Geraldine
authors.initials: G
authors.lastname: Piel
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000008:administration & dosage* / Q000627:therapeutic use; D001812:Blood-Brain Barrier / Q000187:drug effects / Q000378:metabolism / Q000473:pathology; D001921:Brain / Q000187:drug effects* / Q000378:metabolism / Q000473:pathology; D001932:Brain Neoplasms / Q000188:drug therapy* / Q000473:pathology; D004337:Drug Carriers / Q000737:chemistry*; D016503:Drug Delivery Systems / Q000379:methods*; D005909:Glioblastoma / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology; D006801:Humans; D008055:Lipids / Q000737:chemistry; D008081:Liposomes / Q000737:chemistry; D053769:Nanocapsules / Q000737:chemistry; D053758:Nanoparticles / Q000737:chemistry; D011108:Polymers / Q000737:chemistry
chemical_list: D000970:Antineoplastic Agents; D004337:Drug Carriers; D008055:Lipids; D008081:Liposomes; D053769:Nanocapsules; D011108:Polymers
keywords: Blood–brain barrier; Glioblastoma; Lipid nanocapsule; Liposome; Polymeric nanoparticle